Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy.

Xiao GY, Cheng CC, Chiang YS, Cheng WT, Liu IH, Wu SC.

Sci Rep. 2016 Mar 16;6:23120. doi: 10.1038/srep23120.

2.

Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer.

Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC.

Front Oncol. 2015 May 12;5:111. doi: 10.3389/fonc.2015.00111. eCollection 2015.

3.

Glial progenitors as targets for transformation in glioma.

Ilkanizadeh S, Lau J, Huang M, Foster DJ, Wong R, Frantz A, Wang S, Weiss WA, Persson AI.

Adv Cancer Res. 2014;121:1-65. doi: 10.1016/B978-0-12-800249-0.00001-9. Review.

4.

Apoptotic cell death in neuroblastoma.

Li Y, Nakagawara A.

Cells. 2013 Jun 20;2(2):432-59. doi: 10.3390/cells2020432.

5.

Neuroblastoma and MYCN.

Huang M, Weiss WA.

Cold Spring Harb Perspect Med. 2013 Oct 1;3(10):a014415. doi: 10.1101/cshperspect.a014415. Review.

6.

Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.

Rasmuson A, Segerström L, Nethander M, Finnman J, Elfman LH, Javanmardi N, Nilsson S, Johnsen JI, Martinsson T, Kogner P.

PLoS One. 2012;7(12):e51297. doi: 10.1371/journal.pone.0051297. Epub 2012 Dec 17.

7.

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Chen L, Tweddle DA.

Front Oncol. 2012 Nov 28;2:173. doi: 10.3389/fonc.2012.00173. eCollection 2012.

8.

Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.

Jamin Y, Tucker ER, Poon E, Popov S, Vaughan L, Boult JK, Webber H, Hallsworth A, Baker LC, Jones C, Koh DM, Pearson AD, Chesler L, Robinson SP.

Radiology. 2013 Jan;266(1):130-40. doi: 10.1148/radiol.12120128. Epub 2012 Nov 20.

9.

Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.

Veschi V, Petroni M, Cardinali B, Dominici C, Screpanti I, Frati L, Bartolazzi A, Gulino A, Giannini G.

PLoS One. 2012;7(11):e49139. doi: 10.1371/journal.pone.0049139. Epub 2012 Nov 9.

10.

Targeting ALK in neuroblastoma--preclinical and clinical advancements.

Carpenter EL, Mossé YP.

Nat Rev Clin Oncol. 2012 May 15;9(7):391-9. doi: 10.1038/nrclinonc.2012.72. Review.

11.

miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs.

Terrile M, Bryan K, Vaughan L, Hallsworth A, Webber H, Chesler L, Stallings RL.

PLoS One. 2011;6(12):e28356. doi: 10.1371/journal.pone.0028356. Epub 2011 Dec 2.

12.

Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Chesler L, Weiss WA.

Semin Cancer Biol. 2011 Oct;21(4):245-55. doi: 10.1016/j.semcancer.2011.09.011. Epub 2011 Sep 21. Review.

13.

Preclinical models for neuroblastoma: establishing a baseline for treatment.

Teitz T, Stanke JJ, Federico S, Bradley CL, Brennan R, Zhang J, Johnson MD, Sedlacik J, Inoue M, Zhang ZM, Frase S, Rehg JE, Hillenbrand CM, Finkelstein D, Calabrese C, Dyer MA, Lahti JM.

PLoS One. 2011 Apr 29;6(4):e19133. doi: 10.1371/journal.pone.0019133.

14.

Targeting p53-null neuroblastomas through RLIP76.

Singhal J, Yadav S, Nagaprashantha LD, Vatsyayan R, Singhal SS, Awasthi S.

Cancer Prev Res (Phila). 2011 Jun;4(6):879-89. doi: 10.1158/1940-6207.CAPR-11-0025. Epub 2011 Mar 16.

15.
16.

Targeting gastrin-releasing peptide as a new approach to treat aggressive refractory neuroblastomas.

Paul P, Gillory LA, Kang J, Qiao J, Chung DH.

Surgery. 2011 Mar;149(3):425-32. doi: 10.1016/j.surg.2010.08.011. Epub 2010 Oct 29.

17.

Biocompatibility and reduced drug absorption of sol-gel-treated poly(dimethyl siloxane) for microfluidic cell culture applications.

Gomez-Sjoberg R, Leyrat AA, Houseman BT, Shokat K, Quake SR.

Anal Chem. 2010 Nov 1;82(21):8954-60. doi: 10.1021/ac101870s. Epub 2010 Oct 11.

18.

miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.

Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L'Etoile N, Goga A.

Nat Med. 2010 Oct;16(10):1134-40. doi: 10.1038/nm.2227. Epub 2010 Sep 26.

19.

p53 is a direct transcriptional target of MYCN in neuroblastoma.

Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA.

Cancer Res. 2010 Feb 15;70(4):1377-88. doi: 10.1158/0008-5472.CAN-09-2598. Epub 2010 Feb 9.

20.

Myc proteins as therapeutic targets.

Gustafson WC, Weiss WA.

Oncogene. 2010 Mar 4;29(9):1249-59. doi: 10.1038/onc.2009.512. Epub 2010 Jan 25.

Supplemental Content

Support Center